>Interest income 887,636 172,873
Loss before income taxes (4,139,493) (2,729,454)
Provision for income taxes - -
Net loss $(4,139,493) $(2,729,454)
Net loss per share - basic and diluted $ (0.33) $ (0.36)
Weighted average shares outstanding
- basic and diluted 12,525,405 7,687,630
CATALYST PHARMACEUTICAL PARTNERS, INC.
(a development stage company)
CONDENSED BALANCE SHEETS
December 31,
2007 2006
ASSETS
Current assets:
Cash and cash equivalents $15,943,896 $20,434,702
Interest receivable 63,709 85,787
Prepaid expenses 524,081 67,333
Total current assets 16,531,686 20,587,822
Property and equipment, net 127,788 20,157
Deposits 20,448 11,500
Total assets $16,679,922 $20,619,479
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities:
Accounts payable $219,866 $448,072
Accrued expenses and other liabilities 83,419 324,774
Total current liabilities 303,285 772,846
Accrued expenses and other liabilities,
non current 53,880 -
Total liabilities 357,165 772,846
'/>"/>
SOURCE Catalyst Pharmaceutical Partners Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction2.
Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline3.
Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)4.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML5.
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia6.
DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,9477.
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients8.
WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO9.
Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)10.
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)11.
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India